Followers | 61 |
Posts | 9563 |
Boards Moderated | 0 |
Alias Born | 03/29/2015 |
Wednesday, April 01, 2015 6:18:47 PM
It is not so much fickleness as the very real understanding that with companies like NWBO, getting in too early is even worse than getting in too late.
Get in too late and you miss out on the chance to make a huge profit and maybe even overpay a bit.
Get in too early and you get diluted again and again and end up with a reward that is not justified by the risk you took, assuming you end up with anything at all.
If the retail investors have a "give me it" now mentality, this is in large part because NWBO has encouraged this way of thinking only to consistently dash expectations when the moment of truth arrives. The Delay of Phase 3 by a whole year is the biggest example and the failure to release Direct results in March 2015 as promised is the most recent case. Those who have been around longer could cite more.
You cannot blame retail investors from getting fatigued by this kind of consistent over-promising and under-delivering.
In fairness though if NWBO does not have to rely so heavily on Direct.
Since we both agree that DCVax L is good, why doesn't NWBO prioritize finishing up HE reimbursement negotiations?
That would bring revenues in the door and prove DCVax works in the real world which is more important than any trial since trials are simply an imperfect way of simulating real world results.
So what if we have to take a haircut on the price for L?
If we start saving lives in public and start booking revenue in public that changes the whole conversation.
We would still need financing but it would not be dilutive.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM